| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
39,551 |
28,317 |
$4.78M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
19,528 |
15,362 |
$2.86M |
| Y7506 |
|
18,146 |
17,376 |
$2.60M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
8,761 |
6,047 |
$1.98M |
| X4011 |
State-specific procedure code |
4,219 |
3,979 |
$913K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,338 |
9,802 |
$822K |
| X4006 |
|
1,097 |
952 |
$791K |
| 80053 |
Comprehensive metabolic panel |
8,233 |
7,837 |
$624K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,391 |
2,338 |
$431K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
4,615 |
4,453 |
$389K |
| X4003 |
|
3,513 |
3,309 |
$300K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,037 |
7,337 |
$238K |
| 62323 |
|
1,391 |
668 |
$229K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,155 |
4,065 |
$225K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
2,475 |
2,364 |
$195K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,620 |
1,548 |
$194K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,564 |
1,244 |
$156K |
| 87081 |
|
1,437 |
1,400 |
$154K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,737 |
2,635 |
$115K |
| 71045 |
Radiologic examination, chest; single view |
2,041 |
1,922 |
$113K |
| 71046 |
Radiologic examination, chest; 2 views |
410 |
403 |
$111K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,184 |
1,126 |
$56K |
| 81001 |
|
1,577 |
1,527 |
$54K |
| 81003 |
|
2,985 |
2,544 |
$46K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,495 |
1,443 |
$38K |
| 83690 |
|
981 |
946 |
$29K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
510 |
498 |
$29K |
| 64615 |
|
233 |
119 |
$28K |
| 86140 |
|
136 |
131 |
$25K |
| 62321 |
|
126 |
65 |
$24K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
186 |
158 |
$19K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
876 |
835 |
$18K |
| 87428 |
|
524 |
520 |
$16K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
323 |
309 |
$14K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
191 |
179 |
$12K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
191 |
179 |
$12K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
89 |
89 |
$11K |
| 84145 |
|
32 |
30 |
$10K |
| 81025 |
|
1,023 |
997 |
$10K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
66 |
65 |
$9K |
| 98928 |
|
275 |
154 |
$8K |
| 87807 |
|
357 |
352 |
$8K |
| 70450 |
Computed tomography, head or brain; without contrast material |
56 |
52 |
$7K |
| 84484 |
|
379 |
354 |
$7K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
334 |
316 |
$6K |
| 87400 |
|
357 |
349 |
$5K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
26 |
26 |
$5K |
| 95886 |
|
15 |
12 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
317 |
311 |
$4K |
| 83735 |
|
44 |
41 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
125 |
124 |
$4K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
15 |
13 |
$3K |
| 87430 |
|
236 |
235 |
$3K |
| 74022 |
|
12 |
12 |
$2K |
| 87420 |
|
204 |
199 |
$2K |
| 27096 |
|
23 |
12 |
$2K |
| 80306 |
|
31 |
29 |
$2K |
| J3490 |
Unclassified drugs |
278 |
260 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
18 |
17 |
$1K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
216 |
188 |
$1K |
| 85018 |
|
574 |
571 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
28 |
26 |
$953.72 |
| 84443 |
Thyroid stimulating hormone (TSH) |
13 |
13 |
$587.76 |
| 98927 |
|
18 |
14 |
$528.06 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
170 |
167 |
$329.30 |
| 81002 |
|
19 |
13 |
$109.63 |
| 85610 |
|
29 |
28 |
$30.87 |
| 85651 |
|
12 |
12 |
$23.87 |